-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on July 14, the pharmaceutical and biological sector moved .
Among them, Weixinkang Erlian Board, Purui Ophthalmology, Guangzheng Ophthalmology, and Kaikai Industrial had their daily lim.
Watson Pharmaceutical also hit the daily lim.
, as well as He's Ophthalmology, Saisheng Pharmaceutical, Kanghui Pharmaceutical, Opcon Vision, Aier Ophthalmology and many other stocks ro.
Among them, Weixinkang walked out of the second consecutive boa.
As of 13:26, the stock price was 165 yuan, the turnover was 152 million, the turnover rate was 11%, and the price-earnings (TTM) was 46On the news, the company recently released the 2022 semi-annual performance pre-increase announceme.
It is expected that the net profit attributable to shareholders of the listed company in the first half of 2022 will be 96514 million yuan to 109 million yuan, an increase of 85%-105% year-on-ye.
According to the data, Weixinkang is a comprehensive pharmaceutical enterprise, with R&D, production and sales of chemical preparations and APIs as its main business, and has strong competitiveness in the fields of multivitamins, trace elements, electrolytes and other fiel.
Purui Ophthalmology hit the daily limit tod.
As of 13:26, the quotation was 707 yuan, the turnover was 530 million, the turnover rate was 212%, and the price-earnings (TTM) was 105The company is a professional chain ophthalmic medical institution integrating outpatient, clinical, medical and medical technology developme.
Its main business is to provide professional ophthalmic medical services to patients with ophthalmic diseas.
Its products or services mainly include refractive items, cataract items, Medical optometry projects and comprehensive eye disease projects, including refractive surgery, medical optometry, cataract, glaucoma, strabismus and amblyopia and pediatric eye diseases, fundus diseases, eye plastic and lacrimal duct, corneal diseases and other ophthalmic general diagnosis and treatment projec.
On the news, with the advent of the summer vacation, the demand for OK lenses (also known as "orthokeratology lenses") in major eye hospitals has increas.
Clinical Application Management Standard (Draft for Comments)", the new draft for comments cancels the requirement of "secondary (including second-level) and above medical institutions" in the basic conditions for fitting OK mirrors
This also means that the qualification requirements for the downstream sales terminals of OK mirrors are relaxed, and the overall penetration rate of the OK mirror industry may further increa.
In addition to Purui Ophthalmology, ophthalmology concept stocks rose collectively on the 14th, and Guangzheng Ophthalmology also had a daily lim.
As of 13:26, the stock price was 82 yuan, the turnover was 764 million, the turnover rate was 16%, and the price-earnings (TTM) loss was lo.
The main products and services of Guangzheng Ophthalmology include refractive items, cataract items, anterior segment items, posterior segment items, and optometry service ite.
Its ophthalmology business has involved medical beauty business and has carried out ophthalmic plastic surgery ite.
Kaikai Industrial exceeded the daily limit of 1
As of 13:26, the quotation was 198 yuan, the turnover was 173 million, the turnover rate was 98%, and the price-earnings (TTM) was 97According to the data, Kaikai Industry is a listed company whose main business is clothing and medici.
The company is mainly engaged in the production, wholesale and retail of shirts and sweaters, as well as the wholesale and retail of Chinese and Western patent medicin.
In addition, Watson Pharmaceuticals also hit the daily limit tod.
As of 13:26, the stock rose 73%, with a quotation of 184 yuan, a turnover of 160 million, a turnover rate of 93%, and a price-earnings (TTM) of 65In the news, the company has recently received the "Approval Notice for Supplementary Drug Application" approved and issued by the State Food and Drug Administration for "Xanthium rhinitis capsules (registration classification: traditional Chinese medicine; specifications: 4g per capsule)", marking the The product has completed the change of drug marketing authorization holder, and the company has become its drug marketing authorization hold.
According to the data, the company is a comprehensive pharmaceutical enterprise integrating drug research and development, production and sales, and its business formats cover the pharmaceutical industry, pharmaceutical commerce and pharmaceutical reta.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, Weixinkang Erlian Board, Purui Ophthalmology, Guangzheng Ophthalmology, and Kaikai Industrial had their daily lim.
Watson Pharmaceutical also hit the daily lim.
, as well as He's Ophthalmology, Saisheng Pharmaceutical, Kanghui Pharmaceutical, Opcon Vision, Aier Ophthalmology and many other stocks ro.
Among them, Weixinkang walked out of the second consecutive boa.
As of 13:26, the stock price was 165 yuan, the turnover was 152 million, the turnover rate was 11%, and the price-earnings (TTM) was 46On the news, the company recently released the 2022 semi-annual performance pre-increase announceme.
It is expected that the net profit attributable to shareholders of the listed company in the first half of 2022 will be 96514 million yuan to 109 million yuan, an increase of 85%-105% year-on-ye.
According to the data, Weixinkang is a comprehensive pharmaceutical enterprise, with R&D, production and sales of chemical preparations and APIs as its main business, and has strong competitiveness in the fields of multivitamins, trace elements, electrolytes and other fiel.
Purui Ophthalmology hit the daily limit tod.
As of 13:26, the quotation was 707 yuan, the turnover was 530 million, the turnover rate was 212%, and the price-earnings (TTM) was 105The company is a professional chain ophthalmic medical institution integrating outpatient, clinical, medical and medical technology developme.
Its main business is to provide professional ophthalmic medical services to patients with ophthalmic diseas.
Its products or services mainly include refractive items, cataract items, Medical optometry projects and comprehensive eye disease projects, including refractive surgery, medical optometry, cataract, glaucoma, strabismus and amblyopia and pediatric eye diseases, fundus diseases, eye plastic and lacrimal duct, corneal diseases and other ophthalmic general diagnosis and treatment projec.
On the news, with the advent of the summer vacation, the demand for OK lenses (also known as "orthokeratology lenses") in major eye hospitals has increas.
Clinical Application Management Standard (Draft for Comments)", the new draft for comments cancels the requirement of "secondary (including second-level) and above medical institutions" in the basic conditions for fitting OK mirrors
This also means that the qualification requirements for the downstream sales terminals of OK mirrors are relaxed, and the overall penetration rate of the OK mirror industry may further increa.
In addition to Purui Ophthalmology, ophthalmology concept stocks rose collectively on the 14th, and Guangzheng Ophthalmology also had a daily lim.
As of 13:26, the stock price was 82 yuan, the turnover was 764 million, the turnover rate was 16%, and the price-earnings (TTM) loss was lo.
The main products and services of Guangzheng Ophthalmology include refractive items, cataract items, anterior segment items, posterior segment items, and optometry service ite.
Its ophthalmology business has involved medical beauty business and has carried out ophthalmic plastic surgery ite.
Kaikai Industrial exceeded the daily limit of 1
As of 13:26, the quotation was 198 yuan, the turnover was 173 million, the turnover rate was 98%, and the price-earnings (TTM) was 97According to the data, Kaikai Industry is a listed company whose main business is clothing and medici.
The company is mainly engaged in the production, wholesale and retail of shirts and sweaters, as well as the wholesale and retail of Chinese and Western patent medicin.
In addition, Watson Pharmaceuticals also hit the daily limit tod.
As of 13:26, the stock rose 73%, with a quotation of 184 yuan, a turnover of 160 million, a turnover rate of 93%, and a price-earnings (TTM) of 65In the news, the company has recently received the "Approval Notice for Supplementary Drug Application" approved and issued by the State Food and Drug Administration for "Xanthium rhinitis capsules (registration classification: traditional Chinese medicine; specifications: 4g per capsule)", marking the The product has completed the change of drug marketing authorization holder, and the company has become its drug marketing authorization hold.
According to the data, the company is a comprehensive pharmaceutical enterprise integrating drug research and development, production and sales, and its business formats cover the pharmaceutical industry, pharmaceutical commerce and pharmaceutical reta.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
